Skip to main content

Oncology Central is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • News
  • Events coverage
  • Features
    • Opinion
    • Journal articles
    • Events calendar
    • Spotlights
    • In Focus

    Follow us on social media

  • Our Journals
  • Topic
    • Prevention, detection and screening
      • Biomarkers
      • Diagnostics
      • Epidemiology
      • Genetics & genomics
      • Prevention & screening
    • Bench to bedside
      • Cancer biology
      • Clinical trials
      • Drug approvals
      • Drug development
      • Emerging technologies
      • Industry & business
      • Preclinical research
    • Treatments
      • Chemotherapy
      • Immuno-oncology
      • Personalized & precision medicine
      • Radiology
      • Surgery
      • Targeted therapies
    • Supportive oncology
      • Palliative care
      • Patient perspectives
      • Quality of life
      • Survivorship
      • Virtual healthcare

    Follow us on social media

  • Disease specialty
    • Breast
    • Colorectal
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Gynecologic
    • Head & neck
    • Hematologic
    • Hepatic
    • Lung
    • Neurologic
    • Pancreatic
    • Prostate
    • Rare tumors
    • Renal
    • Skin

    Follow us on social media

  • Multimedia
    • Videos
    • Podcasts
    • Infographics
    • Webinars
    • Downloadable eBooks

    Follow us on social media

  • Register
[COFFEE CHAT] The emotional and psychological impact of hepatocellular carcinoma on patients, families and caregivers WATCH NOW

Chemotherapy

Chemotherapy can be used as a primary curative treatment for cancer, generally for highly sensitive germ cell tumors, high-grade lymphomas or solid childhood tumors.

View more

It can also be utilized as an adjuvant treatment whereby systemic chemotherapy is applied in addition to local treatment of the primary lesion in order to try and destroy disseminated, undetectable micro-metastases. Adjuvant chemotherapy is most commonly used for breast cancer. The direct administration of cytotoxic agents to the tumor can also help shrink tumors in the liver or kidney.

Additionally, chemotherapy can be a general palliative treatment in cases where there is unlikely to be a full cure, but chemotherapy can improve the patient’s quality of life and in some cases prolong lifespan. Moreover, cytotoxic chemotherapy can help with palliation of distressing local symptoms.

Success with chemotherapy in curing hematologic and childhood malignancies has spurred on the use of this treatment modality to treat solid tumors, which were previously only treated using surgery or radiotherapy.

Unfortunately, chemotherapy is also associated with unwanted effects as it is not only toxic to cancerous cells but also to normal cells that have a rapid turnover rate e.g., bone marrow and the gastrointestinal epithelium. Toxic effects include bone marrow suppression, immunosuppression, nausea, vomiting, disruption of the gastrointestinal epithelial turnover, hair loss, gonadal effects such as loss of libido/ sterility as well as renal failure.

Types of chemotherapeutic agents are antimetabolites, alkylating agents, drugs that crosslink DNA (e.g., cisplatin) and drugs that disrupt the mitotic spindle. For treating cancer, the best clinical results and the least toxic effects are obtained by using a combination of different cytotoxic drugs.

  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Expert Panel
  • Journals
  • Permissions and content ownership policy
  • Press release policy
  • Whitelist emails

Contact

Contact Us

Office info

Oncology Central is powered by Taylor & Francis Group

Oncology Central, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Oncology Central